CD274 and neoplasm: Using CPS to measure tumor and immune cell PD-L1 expression among recurrent or metastatic HNSCC demonstrates that >80% of cases express PD-L1 at a cutoff of 1 or greater by IHC, but recognizing that an estimated 40% of tumors have scores ≥20 (38).